Sort
326,823 grants matching “clinical trial”
Upper Gastrointestinal Cancer Studies
$2,801,956Sanford M Dawsey · Division Of Cancer Epidemiology And Genetics · ZIA · FY2020 · CA
Understanding and Overcoming T cell Immunosuppression in Glioblastoma
$2,801,934E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2022 · CA
Advancing Hormone Therapy for Endometrial Cancer
$2,801,881Kimberly K Leslie · University Of New Mexico Health Scis Ctr · P01 · FY2025 · CA
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
$2,801,829Judith S. Currier · University Of California Los Angeles · UM1 · FY2024 · AI
Evaluating utility and improving implementation of genomic sequencing for pediatric cancer patients in the diverse population and healthcare settings of Texas: The KidsCanSeq Study
$2,801,395Sharon Emma Plon · Baylor College Of Medicine · U01 · FY2017 · HG
University of Kentucky Alzheimer's Disease Research Center
$2,801,205Linda J Van Eldik · University Of Kentucky · P30 · FY2025 · AG
Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment
$2,800,993David E Fisher · Massachusetts General Hospital · P01 · FY2024 · CA
SPORE in Skin Cancer
$2,800,906Brigham And Women'S Hospital · P50 · FY2002 · CA
NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
$2,800,338Norman Wolmark · Nsabp Foundation, Inc. · U10 · FY2011 · CA
Randomized ESRD Trial COmparing CBT alone VERsus with buprenorphine (RECOVER)
$2,800,151Rajnish Mehrotra · University Of Washington · U01 · FY2019 · DK
Childhood Liver Disease Research Network Data Coordinating Center
$2,800,068John C Magee · University Of Michigan At Ann Arbor · U01 · FY2014 · DK
IGF::OT::IGF - GTRP CLINICAL COORDINATING CENTER; TO.5; TASK AREA B; CLINICAL TRIALS; FY15; CAN 8470187; AMT $2,800,040.
$2,800,040Sue Sepelak · Social And Scientific Systems, Inc. · N01 · FY2015 · HL
Development of Ad26/Env Vaccines for HIV
$2,800,000Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2018 · AI
Development of Ad26/Env Vaccines for HIV
$2,800,000Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2021 · AI
Rho Federal Systems Division, Inc. NIAID DAIT SACCC
$2,800,000Gloria David · Rho Federal Systems Division, Inc. · UM2 · FY2023 · AI
Molecular Transducers of Physical Activity Consortium Coordinating Center
$2,800,000Michael E. Miller · Wake Forest University Health Sciences · U24 · FY2024 · AR
All of Us Research Program Heartland Consortium (AoURP-HC)
$2,800,000Akinlolu O Ojo · University Of Kansas Medical Center · OT2 · FY2024 · OD
Development of Ad26/Env Vaccines for HIV
$2,799,999Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2019 · AI
Development of Ad26/Env Vaccines for HIV
$2,799,999Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2020 · AI
Development of Ad26/Env Vaccines for HIV
$2,799,999Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2022 · AI
Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes - Biostatistics Research Center
$2,799,925Barbara Halina Braffett · George Washington University · U01 · FY2024 · DK
Hormone-Related Cancers
$2,799,580Gretchen Gierach · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA
Appalachian Node
$2,799,142Jane M Liebschutz · University Of Pittsburgh At Pittsburgh · UG1 · FY2019 · DA
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.
$2,798,940Hugh William Alsop · Kinoxis Therapeutics Pty Ltd · UG3 · FY2019 · DA
Mechanisms of Sensory Hair Cell Survival and Death
$2,798,822Lisa L Cunningham · National Institute On Deafness And Other Communication Disorders · ZIA · FY2024 · DC